Robotic CT guidance: the case is strongest where the trajectory is hardest

Design

Narrative review conducted to SANRA principles, mapped onto the IDEAL framework

Population

Preclinical, feasibility and comparative clinical studies of robotic CT-guided percutaneous intervention

Primary outcome

Targeting accuracy, needle adjustments, radiation exposure, procedure time and evidence maturity

Effect

Consistently better targeting and fewer needle adjustments preclinically; operator dose frequently reduced; procedure time and patient dose variable; most evidence at IDEAL stages 1-2b

CT-guided intervention remains operator-dependent in a way most of interventional radiology has moved past, and robotic needle guidance has been proposed as the answer. This narrative review searched PubMed, Scopus and trial registries and mapped what it found onto the IDEAL framework, the staged scheme for evaluating procedural innovation from idea through to long-term study.

Preclinical work consistently shows better targeting accuracy and fewer needle adjustments than freehand technique. Clinical evidence supports feasibility and safety across biopsy and ablation, concentrated in the liver, lung, kidney and musculoskeletal system, and specifically in long, oblique and out-of-plane trajectories - the procedures where freehand technique costs the most passes. Operator radiation exposure is frequently reduced. Procedure time and patient dose effects are variable, which is a polite way of saying they sometimes go the wrong way.

The framework placement is the honest part of the review. Most published studies sit at IDEAL stages 1 to 2b - development and exploration - with randomised stage 3 evaluation only emerging and registry data thin. The authors' conclusion is that these are precision-enabling technologies, not standard of care, and that selective use in technically complex procedures is what the evidence currently supports. For a department weighing the purchase, the question to ask is how many of its cases actually involve the long oblique trajectory where the benefit is concentrated.

• The benefit case rests on long, oblique and out-of-plane trajectories, not routine biopsies
• Operator dose reduction is the most consistent advantage reported
• Do not assume shorter procedures or lower patient dose; both were variable
• Ask how many cases per year in your unit fit the complex-trajectory profile before costing a system
• IDEAL stage 1-2b means development-stage evidence - randomised comparison is only starting

Why it matters

It separates the procedures where robotic guidance has evidence from the ones it is being sold for.

Don't overread it

A narrative review of mostly development-stage studies; there is no randomised evidence of clinical benefit yet.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.